Shares of Universal Health Realty Income Trust (UHT) have gained 0.2% since the company reported its earnings for the quarter ended March 31, 2025. This compares to the S&P 500 Index’s 0.6% gain over the same time frame. Over the past month, the stock lost 6.7%, underperforming the broader market’s 0.6% decline.For the first quarter of 2025, Universal Health Realty reported a net income of $4.8 million, compared with $5.3 million in the prior-year period. This 9.9% decline in net income was primarily attrib ...

Core Viewpoint - Regeneron Pharmaceuticals reported disappointing first-quarter 2025 results, with adjusted EPS of $8.22, missing estimates and down 14% year-over-year, primarily due to lower revenues and higher operating expenses [1][2][17] Financial Performance - Total revenues decreased 4% year-over-year to $3 billion, missing the Zacks Consensus Estimate of $3.27 billion, driven by lower sales of Eylea and Libtayo [2][17] - Eylea sales in the U.S. plummeted 39% year-over-year to $736 million, impacted by increased competition and market share loss [4][17] - Total Eylea and Eylea HD sales in the U.S. were $1 billion, down 26% year-over-year, also missing estimates [7][17] - Collaboration revenues from Sanofi and Bayer totaled $1.53 billion, up 20.9% year-over-year, exceeding estimates [8][9] Product Performance - Sanofi's collaboration revenues increased 30% to $1.2 billion, driven by higher Dupixent sales, which rose 19% year-over-year to $3.7 billion [9] - Libtayo sales were $285.1 million, up 8% year-over-year, but missed estimates [10] - Eylea HD generated $307 million in revenues, a 54% increase year-over-year, but total Eylea and Eylea HD sales were still down significantly [6][7] Cost and Expenses - Gross margin decreased to 85% from 89% due to higher inventory write-offs and reserves [11] - Adjusted R&D expenses rose 6% year-over-year to $1.2 billion, while adjusted SG&A expenses decreased 8% to $537 million [11] Shareholder Actions - The board authorized a new share repurchase program for up to $3 billion, with $1.052 billion repurchased in Q1 2025 [12] - A cash dividend of $0.88 per share was declared in April 2025 [12] Regulatory Updates - The FDA approved a label expansion for Dupixent and accepted applications for Eylea HD and other drugs, but also issued complete response letters for some applications [13][14][15][16] Strategic Developments - Regeneron entered a 10-year agreement with Fujifilm Diosynth Biotechnologies to enhance manufacturing capacity in the U.S. [19]

Core Insights - Hilton Worldwide Holdings Inc. reported first-quarter adjusted earnings per share of $1.72, exceeding the street view of $1.61 [1] - Quarterly sales reached $2.69 billion, which fell short of the analyst consensus estimate of $2.72 billion [1] - Adjusted EBITDA for the first quarter was $795 million, an increase from $750 million a year ago, with an expanded adjusted EBITDA margin of 73.7% compared to 70.4% in the previous year [1] Financial Performance - System-wide comparable RevPAR increased by 2.5% on a currency-neutral basis for the first quarter compared to the same period in 2024 [2] - Quarterly net income margin improved to 11.1% from 10.4% [2] - The company opened 186 hotels, adding a total of 20,100 rooms, resulting in 14,000 net room additions during the first quarter of 2025 [2] Strategic Developments - The company expanded its pipeline of lifestyle properties, introducing the Tempo by Hilton brand in the U.K., marking its first hotel outside the U.S., along with new hotels in Greece and Utah [3] - As of March 31, the company had $11.2 billion in outstanding debt, excluding deferred financing costs and discounts [3] Cash Management - Total cash and equivalents amounted to $807 million as of March 31, 2025, which included $76 million of restricted cash [4] - The firm repurchased 3.7 million shares of common stock during the first quarter, leading to a total capital return of $927 million for the quarter and $1,157 million year-to-date through April [4] - The board of directors authorized a regular quarterly cash dividend of $0.15 per share to be paid on June 27 [4] Future Outlook - Hilton raised its full-year 2025 adjusted EPS guidance to a range of $7.76–$7.94, up from the previous range of $7.71–$7.82, which compares favorably to the $7.93 analyst estimate [5] - For the second quarter, the company expects adjusted EPS between $1.97 and $2.02, which is below the $2.11 estimate [5] - HLT shares were trading lower by 1.30% to $224.27 at the last check on Tuesday [5]

Financial Data and Key Metrics Changes - InMode generated total revenue of $77.9 million in Q1 2025, a decrease of 3% compared to Q1 2024 [8] - GAAP gross margin was 78% in Q1 2025, down from 80% in Q1 2024 [8] - Non-GAAP diluted earnings per share were $0.31, compared to $0.32 in Q1 2024 [12] Business Line Data and Key Metrics Changes - Minimally invasive platforms accounted for 87% of total revenues in Q1 2025 [9] - Sales and marketing expenses decreased slightly to $39.7 million in Q1 2025 from $39.8 million in the same period last year [11] Market Data and Key Metrics Changes - International sales accounted for $38 million or 49% of total sales, a 1% increase compared to Q1 2024 [10] - Europe was the largest revenue contributor from outside the U.S., achieving record sales [10] Company Strategy and Development Direction - The company plans to unveil a new platform for the wellness market later in 2025, aiming to diversify its product offerings [6] - InMode remains committed to maintaining its workforce and not cutting costs, believing this will position the company to lead when market conditions improve [5] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing macroeconomic uncertainty and soft consumer demand affecting the medical aesthetic market [4] - The company anticipates a potential reduction in operating margins by 4% to 5% due to market pressures and U.S. tariffs [13] Other Important Information - InMode completed a share repurchase program, buying back 6.95 million shares for $127 million, returning over $412 million to shareholders in the past year [7] - The company has a strong balance sheet with cash and equivalents totaling $512.9 million as of March 31, 2025 [12] Q&A Session Summary Question: Follow-up on product mix dynamics - Management indicated that the slowdown began in mid-2023 due to rising interest rates and decreased consumer confidence, impacting capital equipment purchases [19] Question: Guidance for Q2 and market recovery - Management expressed optimism for Q2 but noted that if results do not improve significantly, guidance may need to be lowered [30] Question: Impact of tariffs on gross margins - Management explained that current tariffs could impact gross margins by approximately 2% to 3% if they remain at 10% [56] Question: Updates on operating expenses - Management confirmed that they plan to maintain investments in sales and marketing despite macro challenges [63] Question: Pricing strategy in the current market - Management decided against raising prices due to the current market conditions, emphasizing the importance of maintaining competitiveness [70] Question: Performance in Europe compared to the U.S. - Management noted that Europe performed better in Q1 2025, attributed to management changes and pricing strategies [83]

Financial Data and Key Metrics Changes - InMode generated total revenue of $77.9 million in Q1 2025, a decrease of 3% compared to Q1 2024 [8] - GAAP gross margin was 78% in Q1 2025, down from 80% in Q1 2024 [8] - Non-GAAP diluted earnings per share were $0.31, compared to $0.32 in Q1 2024 [12] - The company ended the quarter with cash and cash equivalents of $512.9 million [12] Business Line Data and Key Metrics Changes - Minimally invasive platforms accounted for 87% of total revenues in Q1 2025 [9] - Sales and marketing expenses decreased slightly to $39.7 million in Q1 2025 from $39.8 million in Q1 2024 [11] Market Data and Key Metrics Changes - International sales accounted for $38 million or 49% of total sales, a 1% increase compared to Q1 2024 [9] - Europe was the largest revenue contributor from outside the U.S., achieving record sales [10] Company Strategy and Development Direction - The company plans to unveil a new platform for the wellness market later this year, reflecting its strategy to diversify offerings [6] - InMode has committed to not reducing its workforce and aims to lead the industry during the market rebound [6] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing macroeconomic uncertainty and soft consumer demand affecting the medical aesthetic market [4] - The company anticipates a potential reduction in operating margins by 4% to 5% due to market pressures and U.S. tariffs [13] - Management remains optimistic about a market recovery, contingent on Q2 performance [30] Other Important Information - InMode returned over $412 million to shareholders through share repurchases over the past twelve months, representing approximately 27% of total capital [7] - The company has not yet hired a new President for the U.S. and is currently led by the acting President [66] Q&A Session Summary Question: Follow-up on product mix dynamics - Management indicated that the slowdown began in mid-2023 due to rising interest rates and decreased consumer confidence, impacting capital equipment purchases [20][21] Question: Guidance for Q2 and market trends - Management expects Q2 to be stronger than Q1, but if results do not improve, guidance may need to be lowered [31][40] Question: Impact of tariffs on guidance - Tariffs are expected to impact gross margins by approximately 2% to 3% if they remain at 10% [57][79] Question: Updates on operating expenses - The company plans to maintain its investment in sales and marketing despite macro challenges, which may impact profitability [65] Question: Pricing strategy in the current market - Management decided not to raise prices due to the current market conditions, despite tariff impacts [70][90] Question: Performance in Europe compared to the U.S. - Europe has shown better performance due to management changes and pricing strategies, although credit conditions are tightening [83]

Due to the essentiality of healthcare, the medical sector can provide a defensive hedge against market uncertainty, and investors may be eyeing AbbVie (ABBV)  and HCA Healthcare (HCA)  stock ahead of their Q1 reports on Friday, April 25.Being the largest non-governmental operator of acute care hospitals in the United States, HCA shares are up a very respectable +11% year to date, with pharmaceutical giant AbbVie’s stock virtually flat but outperforming the benchmark S&P 500’s 10% decline as well. That said, ...

Core Viewpoint - Great Southern Bancorp, Inc. (GSBC) is currently on sale amid a stock market sell-off, with a Zacks Rank of 1 (Strong Buy) and expected earnings growth of 7.6% in 2025 [1][13]. Company Overview - Great Southern Bancorp is the holding company for Great Southern Bank, founded in 1923 in Springfield, Missouri, and has expanded to 97 offices across 12 states [1]. - The company has a market capitalization of $619 million [3]. Financial Performance - In the first quarter of 2025, Great Southern Bancorp reported preliminary earnings of $1.47, exceeding the Zacks Consensus estimate of $1.26 by $0.21 [4]. - The company has beaten earnings estimates in 4 out of the last 5 quarters [5]. - Net interest income for the quarter increased by $4.5 million, or approximately 10.1%, to $49.3 million compared to $44.8 million a year ago, driven by higher interest income on loans and lower interest expenses on deposits [5]. - Total interest income for the first quarter of 2025 was $80.2 million, reflecting higher earning asset levels and loan yields [8]. Asset Quality - As of March 31, 2025, non-performing assets totaled $9.5 million, or 0.16% of total assets, a slight decrease from $9.6 million as of December 31, 2024 [6]. - Problematic loans, including non-performing assets and potential problem loans, amounted to $17 million as of March 31, 2025, an increase from $16.6 million at the end of 2024 [5]. Shareholder Focus - In the first quarter of 2025, the company repurchased 175,000 shares and announced a new stock repurchase program of up to one million additional shares [10]. - The company currently pays a dividend with a yield of 3% [12]. Analyst Outlook - Analysts have revised their estimates for 2025, increasing the Zacks Consensus Estimate from $5.25 to $5.66, indicating an earnings growth of 7.6% from $5.26 in 2024 [13][14]. Valuation Metrics - Great Southern Bancorp's shares have pulled back in 2025, with a price-to-earnings ratio of 9.4, considered cheap [15][18]. - The company has a price-to-book ratio of 1.04, which is close to the threshold of 1.0, indicating a potentially attractive valuation [19].

Company Overview - Unitil (UTL) is a utility company headquartered in Hampton, which has experienced a price change of 8.36% this year [3] - The company currently pays a dividend of $0.45 per share, resulting in a dividend yield of 3.07%, which is higher than the Utility - Electric Power industry's yield of 3.05% and the S&P 500's yield of 1.69% [3] Dividend Performance - Unitil's annualized dividend of $1.80 has increased by 5.9% from the previous year [4] - Over the past five years, Unitil has raised its dividend five times, achieving an average annual increase of 3.51% [4] - The current payout ratio for Unitil is 58%, indicating that the company pays out 58% of its trailing 12-month earnings per share as dividends [4] Earnings Growth Expectations - For the fiscal year 2025, the Zacks Consensus Estimate projects earnings of $3.08 per share, reflecting a year-over-year earnings growth rate of 3.70% [5] Investment Considerations - Dividends are favored by investors for various reasons, including improving stock investing profits and providing tax advantages [6] - It is noted that high-yielding stocks may face challenges during periods of rising interest rates, yet UTL is considered a compelling investment opportunity due to its strong dividend profile [7] - The stock currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [7]

Core Insights - The Travelers Companies (TRV) reported a first-quarter 2025 core income of $1.91 per share, significantly exceeding the Zacks Consensus Estimate of 69 cents, although the bottom line declined 29.3% year over year [1][2] Financial Performance - Total revenues increased by 6.1% year over year to $11.9 billion, driven by higher premiums and net investment income, but fell short of the Zacks Consensus Estimate of $12.1 billion [3] - Net written premiums reached a record $10.5 billion, up 3% year over year, surpassing the estimate of $10.2 billion [3] - Net investment income rose by 9.9% year over year to $930 million, exceeding the estimate of $927 million, although below the Zacks Consensus Estimate of $952 million [4] - Catastrophe losses amounted to $2.3 billion, significantly higher than the $175 million loss in the prior year [4] - Underwriting loss was reported at $305 million, compared to a gain of $577 million in the previous year [4] Underwriting Performance - Underlying underwriting income improved by over 30% year over year to $1.6 billion, supported by strong net earned premiums [5] - The consolidated underlying combined ratio improved by 290 basis points year over year to 84.8, while the overall combined ratio deteriorated by 860 basis points to 102.5 due to increased catastrophe losses [5] Segment Analysis - **Business Insurance**: Net written premiums increased by 2% year over year to approximately $5.7 billion, with a combined ratio of 96.2, down 290 basis points [6] - **Bond & Specialty Insurance**: Net written premiums rose by 6% year over year to $999 million, with a combined ratio improving by 200 basis points to 82.5 [7] - **Personal Insurance**: Net written premiums of $3.8 billion increased by 5% year over year, but the combined ratio deteriorated to 115.2 due to higher catastrophe losses [9][10] Financial Position - Total investments and cash stood at $96.4 billion, reflecting a 1.6% increase from the end of 2024 [11] - Debt remained flat at $8 billion, while operating cash flow decreased by 6.7% year over year to $1.4 billion [11] - Core return on equity contracted by 980 basis points to 5.6% [11] Capital Management - The company returned over $600 million to shareholders through dividends and share repurchases, including the buyback of 1 million shares for $358 million [12] - A 5% increase in the quarterly cash dividend to $1.10 per share was declared, marking 21 consecutive years of dividend increases [13]

Group 1 - The article discusses insights from Bloomberg Intelligence analysts who monitor 2,000 companies across various industries, including apparel, autos, finance, and food [1] - The information is part of the December 2024 Bloomberg Businessweek's annual "The Year Ahead" issue, which is reiterated in the January 2025 edition [1] Group 2 - The article promotes a live video series on Facebook called "Underdog Daily Dividend Show," hosted by Fredrik Arnold, which highlights potential portfolio candidates [2] - The show encourages audience interaction by inviting comments on favorite, least favorite, or curious stock tickers for future reports [2]